What is the recommended dosage of Ivosidenib?

The dosage of Ivosidenib may vary among different patients.

What is the recommended dosage of Ivosidenib?

Please follow the doctor’s instructions or the directions on the label. The information below only includes the average dosage of this medication. Do not adjust your dosage without your doctor’s approval if you are prescribed a different amount.

The dosage administered depends on the strength of the drug. In addition, the frequency of daily administration, the interval between doses, and the duration of treatment are all determined by the specific condition being treated.

Oral dosage form (tablets)

For newly diagnosed acute myeloid leukemia (AML) (in combination with Azacitidine):

a. Adults: 500 mg once daily. Initiate treatment on Day 1 of Cycle 1 in combination with Azacitidine (Azacitidine administered subcutaneously or intravenously once daily on Days 1–7 or Days 1–5 plus Days 8–9 of a 28-day cycle). The doctor may adjust the dosage based on individual patient needs and tolerability.

b. Pediatric patients: The dosage and administration must be determined by the doctor.

For newly diagnosed, relapsed or refractory AML, cholangiocarcinoma (as monotherapy), and myelodysplastic syndromes (MDS):

a. Adults: 500 mg once daily. The doctor may adjust the dosage based on individual patient needs and tolerability.

b. Pediatric patients: The dosage and administration must be determined by the doctor.

Precautions for Contraception and Pregnancy

This product may cause harm to the developing fetus. It is imperative to avoid pregnancy or causing pregnancy in others during treatment with this product and for at least one month after the completion of treatment.

Ivosidenib may reduce the effectiveness of oral contraceptives, contraceptive injections, or implantable contraceptives. If you are using such contraceptive methods, you should additionally use a barrier contraceptive (e.g., condoms) during sexual intercourse.

Discuss effective contraceptive measures with your doctor or nurse before initiating treatment. If you or your partner becomes pregnant during treatment, inform the healthcare provider immediately.

Precautions for Breastfeeding and Other Conditions

Do not breastfeed during treatment and for 1 month after the last dose, as Ivosidenib may be excreted in human milk.

If you are undergoing examinations or treatment for other medical conditions, be sure to inform the treating doctor that you are receiving cancer therapy (e.g., when visiting a dentist).